Annals of translational medicine最新文献

筛选
英文 中文
Erratum to Phosphorylated nuclear factor erythroid 2-related factor 2 promotes the secretion of C-C motif chemokine ligand 2 and the recruitment of M2 macrophages. 磷酸化核因子红细胞2相关因子2促进C-C基序趋化因子配体2的分泌和M2巨噬细胞的募集。
4区 医学
Annals of translational medicine Pub Date : 2025-06-27 Epub Date: 2024-09-21 DOI: 10.21037/atm-2024-17
{"title":"Erratum to Phosphorylated nuclear factor erythroid 2-related factor 2 promotes the secretion of C-C motif chemokine ligand 2 and the recruitment of M2 macrophages.","authors":"","doi":"10.21037/atm-2024-17","DOIUrl":"10.21037/atm-2024-17","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/atm-21-2947.].</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 3","pages":"35"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dazukibart for dermatomyositis: expanding the therapeutic arsenal. 达祖基巴特治疗皮肌炎:扩大治疗库。
4区 医学
Annals of translational medicine Pub Date : 2025-06-27 Epub Date: 2025-06-24 DOI: 10.21037/atm-25-44
Iago Pinal-Fernandez, Maria Casal-Dominguez, Andrew L Mammen
{"title":"Dazukibart for dermatomyositis: expanding the therapeutic arsenal.","authors":"Iago Pinal-Fernandez, Maria Casal-Dominguez, Andrew L Mammen","doi":"10.21037/atm-25-44","DOIUrl":"10.21037/atm-25-44","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 3","pages":"24"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Raltitrexed as a substitute for 5-fluorouracil in combination with pembrolizumab and platinum in a patient with metastatic esophageal squamous cell carcinoma and coronary artery disease: a case report. 雷替曲塞替代5-氟尿嘧啶联合派姆单抗和铂治疗转移性食管鳞状细胞癌合并冠状动脉疾病1例
4区 医学
Annals of translational medicine Pub Date : 2025-06-27 Epub Date: 2025-06-24 DOI: 10.21037/atm-25-38
Matthew Van Oirschot, Saurav Verma, Daniel Breadner, Andrea Vucetic
{"title":"Raltitrexed as a substitute for 5-fluorouracil in combination with pembrolizumab and platinum in a patient with metastatic esophageal squamous cell carcinoma and coronary artery disease: a case report.","authors":"Matthew Van Oirschot, Saurav Verma, Daniel Breadner, Andrea Vucetic","doi":"10.21037/atm-25-38","DOIUrl":"10.21037/atm-25-38","url":null,"abstract":"<p><strong>Background: </strong>Chemoimmunotherapy is the standard treatment for patients with metastatic esophageal squamous cell carcinoma (ESCC), for which 5-fluorouracil (5-FU) is commonly part of the chemotherapy regimen. Given that 5-FU has a mean cardiotoxicity risk of approximately 5%, raltitrexed has often been used as an alternative in patients with a history of fluoropyrimidine-associated cardiotoxicity or significant coronary artery disease (CAD). We report the first case, to our knowledge, of the use of raltitrexed in place of 5-FU in combination with pembrolizumab and platinum-based chemotherapy for the treatment of metastatic esophageal cancer in a patient with CAD.</p><p><strong>Case description: </strong>A 75-year-old gentleman with preexisting multivessel CAD was diagnosed with metastatic gastroesophageal junction (GEJ) squamous cell carcinoma (SCC) after presenting to medical attention with a 2-month history of worsening chest pain in addition to progressive dysphagia associated with weight loss. Following initial treatment with palliative locoregional radiotherapy to the lower mediastinum, GEJ, and upper abdomen, the decision was made to proceed with palliative systemic therapy. Considering his significant cardiac history, 5-FU was replaced with raltitrexed and combined with carboplatin and pembrolizumab. After a total of 10 months of treatment, the patient presented to hospital with recurrent chest pain and was diagnosed with a non-ST-elevation myocardial infarction (NSTEMI). Despite radiographic evidence of stability of his malignancy on systemic therapy, he was not considered to be a candidate for cardiac intervention. He was thus transitioned to a comfort-focused care approach and passed away shortly thereafter, with the cause of death being acute coronary syndrome.</p><p><strong>Conclusions: </strong>Although the patient unfortunately passed away prematurely due to preexisting CAD, there was no evidence of disease progression in the 10 months that he received treatment. In addition to an encouraging progression-free survival (PFS), the patient reported an overall improvement in quality of life while on therapy with no signals of toxicity from raltitrexed or immunotherapy. Overall, the present case demonstrates that chemotherapy in combination with immunotherapy for the treatment of advanced esophageal cancer appears to be safe and effective when raltitrexed is substituted for 5-FU, which is of particular relevance due to the many overlapping characteristics of patients with cardiac pathology and esophageal cancer.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 3","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early restrictive versus liberal oxygen for trauma patients: does it make a difference? 创伤患者早期限制氧与自由氧:有区别吗?
4区 医学
Annals of translational medicine Pub Date : 2025-04-30 Epub Date: 2025-04-29 DOI: 10.21037/atm-25-33
Colin F Mackenzie
{"title":"Early restrictive versus liberal oxygen for trauma patients: does it make a difference?","authors":"Colin F Mackenzie","doi":"10.21037/atm-25-33","DOIUrl":"10.21037/atm-25-33","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 2","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olverembatinib for heavily pretreated BCR::ABL1-positive leukemia, including resistance or intolerance to ponatinib and/or asciminib. Olverembatinib用于重度预处理BCR:: abl1阳性白血病,包括对ponatinib和/或asciminib的耐药或不耐受。
4区 医学
Annals of translational medicine Pub Date : 2025-04-30 Epub Date: 2025-04-29 DOI: 10.21037/atm-25-28
Yasushi Kubota
{"title":"Olverembatinib for heavily pretreated <i>BCR::ABL1</i>-positive leukemia, including resistance or intolerance to ponatinib and/or asciminib.","authors":"Yasushi Kubota","doi":"10.21037/atm-25-28","DOIUrl":"10.21037/atm-25-28","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 2","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels. 每日口服小分子脂蛋白(a)抑制剂muvalaplin在脂蛋白(a)水平升高的高危心血管患者中取得了令人鼓舞的结果。
4区 医学
Annals of translational medicine Pub Date : 2025-04-30 Epub Date: 2025-04-29 DOI: 10.21037/atm-25-40
Alpo Vuorio, Petri T Kovanen, Frederick Raal
{"title":"Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels.","authors":"Alpo Vuorio, Petri T Kovanen, Frederick Raal","doi":"10.21037/atm-25-40","DOIUrl":"10.21037/atm-25-40","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 2","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis. 丁酸盐通过减少内毒素血症和抑制肝气真皮蛋白d介导的焦亡来改善酒精性脂肪肝疾病。
4区 医学
Annals of translational medicine Pub Date : 2025-04-30 Epub Date: 2024-10-28 DOI: 10.21037/atm-2024-14
{"title":"Erratum to butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis.","authors":"","doi":"10.21037/atm-2024-14","DOIUrl":"10.21037/atm-2024-14","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/atm-21-2158.].</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 2","pages":"21"},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to Transthyretin-induced increase in circ_0007411 represses neovascularization of human retinal microvascular endothelial cells in hyperglycemia via the miR-548m/PTPN12/SKP1/EGFR pathway. 经甲状腺素诱导的circ_0007411升高通过miR-548m/PTPN12/SKP1/EGFR通路抑制高血糖时人视网膜微血管内皮细胞的新生血管。
4区 医学
Annals of translational medicine Pub Date : 2025-04-30 Epub Date: 2024-10-08 DOI: 10.21037/atm-2024-13
{"title":"Erratum to Transthyretin-induced increase in circ_0007411 represses neovascularization of human retinal microvascular endothelial cells in hyperglycemia via the miR-548m/PTPN12/SKP1/EGFR pathway.","authors":"","doi":"10.21037/atm-2024-13","DOIUrl":"10.21037/atm-2024-13","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/atm-22-1276.].</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 2","pages":"22"},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optical coherence tomography retinal imaging: narrative review of technological advancements and clinical applications. 光学相干断层扫描视网膜成像:技术进步和临床应用的叙述回顾。
4区 医学
Annals of translational medicine Pub Date : 2025-04-30 Epub Date: 2025-04-29 DOI: 10.21037/atm-24-211
Christopher S Langlo, Aana Amin, Susanna S Park
{"title":"Optical coherence tomography retinal imaging: narrative review of technological advancements and clinical applications.","authors":"Christopher S Langlo, Aana Amin, Susanna S Park","doi":"10.21037/atm-24-211","DOIUrl":"10.21037/atm-24-211","url":null,"abstract":"<p><strong>Background and objective: </strong>Optical coherence tomography (OCT) is a non-invasive imaging tool that can provide rapid cross-sectional images of the retina, cornea, and optic nerve head in live patients. The objective of this review is to provide an overview of the technical advancements and current clinical applications of OCT for managing patients with retinal disorders.</p><p><strong>Methods: </strong>Narrative overview synthesizing the findings of literature retrieved from searches of computerized database, authoritative texts and authors' clinical experience and expertise.</p><p><strong>Key content and findings: </strong>Unlike the first-generation time-domain OCT (TD-OCT) instruments, the newer spectral-domain OCT (SD-OCT) instruments use a broadband light source to increase axial image resolution. In addition, the decreased image acquisition time also increases the transverse image resolution, reduces motion artifacts, and allows serial cross-sectional images of the retina to be obtained rapidly. A three-dimensional (3D) image of the retina, reconstructed using serial two-dimensional (2D) OCT images, can be used to quantitate retinal thickness and volume and perform analysis of retinal topography. Currently, commercial SD-OCT instruments are used routinely in clinical practice to obtain morphologic information used to diagnose and manage patients with various retinal disorders including macular degeneration and diabetic retinopathy. Newer swept-source OCT technology with faster image acquisition, provides wider field imaging of the peripheral retina. SD-OCT instruments can be incorporated into surgical microscopes to allow imaging of the retina during retinal surgery so that morphologic changes in the retina from surgical maneuvers can be observed in real time. More recently, OCT angiography (OCTA) has been developed which allows rapid, non-invasive 3D imaging of retinal and choroidal vascular flow. This is achieved by processing rapid serial SD-OCT images to detect movement of blood cells within vessels. Research has been done to further improve image resolution of SD-OCT to a cellular level by adding adaptive optics (AO) technology. The latest in SD-OCT technology is optoretinography (ORG), a technique to derive functional information from OCT images of the retina.</p><p><strong>Conclusions: </strong>Advancement in OCT technology has made it possible to obtain high resolution retinal images that can provide anatomic, physiologic and functional information of the retina in live patients.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 2","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association of hemorrhoids with the incidence of heart failure: a nationwide cohort study. 痔疮与心力衰竭发病率的关系:一项全国性队列研究。
4区 医学
Annals of translational medicine Pub Date : 2025-04-30 Epub Date: 2025-04-29 DOI: 10.21037/atm-24-218
Ho Geol Woo, Ju-Young Park, Moo-Seok Park, Tae-Jin Song
{"title":"The association of hemorrhoids with the incidence of heart failure: a nationwide cohort study.","authors":"Ho Geol Woo, Ju-Young Park, Moo-Seok Park, Tae-Jin Song","doi":"10.21037/atm-24-218","DOIUrl":"10.21037/atm-24-218","url":null,"abstract":"<p><strong>Background: </strong>Studies evaluating the association between hemorrhoids and heart failure (HF) have been limited. We aimed to evaluate the association between increased incidence of HF and the presence of hemorrhoids using a population-based longitudinal cohort.</p><p><strong>Methods: </strong>We included 356,033 participants in this study, derived from health screening data collected between 2003 and 2007 from the South Korean health screening cohort database. Hemorrhoid presence was identified as having a minimum of two claims based on the International Classification of Diseases, Tenth Revision (ICD-10) code I84. Propensity score matching (PSM) was used to assign participants to two groups according to the presence and treatment of hemorrhoids. The primary outcome was the incidence of HF, defined as having two or more claims based on the ICD-10 code I50.</p><p><strong>Results: </strong>Among the participants, the presence of hemorrhoids was observed in 24,363 (6.8%) individuals. Over a median follow-up period of 13.33 years (interquartile range, 10.4-16.26), 55,167 cumulative cases of HF (15.5%) occurred. In multivariate analysis, the group with hemorrhoids consistently showed a higher incidence of HF compared to those without hemorrhoids, both before [hazard ratio (HR): 1.073; 95% confidence interval (CI): 1.028-1.121] and after PSM (HR: 1.073; 95% CI: 1.018-1.131). Regarding surgical procedures/treatments for hemorrhoids, participants who underwent surgical procedures or treatment for hemorrhoids showed a lower incidence of HF before PSM (HR, 0.919; 95% CI: 0.845-1.001) and after PSM (HR, 0.941; 95% CI: 0.880-1.001).</p><p><strong>Conclusions: </strong>Our study revealed a significantly increased incidence of HF among participants with hemorrhoids. Therefore, it should be noted that when hemorrhoids are present, the risk of developing HF in the future may be increased.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"13 2","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信